Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

112.19B

Market cap112.19B

Price-Earnings ratio

16.05

Price-Earnings ratio16.05

Dividend yield

4.37%

Dividend yield4.37%

Average volume

11.11M

Average volume11.11M

High today

$57.43

High today$57.43

Low today

$54.71

Low today$54.71

Open price

$57.40

Open price$57.40

Volume

10.34M

Volume10.34M

52 Week high

$62.89

52 Week high$62.89

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

With a market cap of 112.19B, Bristol-Myers Squibb(BMY) trades at $54.94. The stock has a price-to-earnings ratio of 16.05 and currently yields dividends of 4.4%.

As of 2026-06-01, Bristol-Myers Squibb(BMY) stock has fluctuated between $54.71 and $57.43. The current price stands at $54.94, placing the stock +0.4% above today's low and -4.3% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 10.34M, compared to an average daily volume of 11.11M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

BMY News

CNBC 3h

Bristol Myers Squibb CEO on $15B deal with China's Hengrui Pharma - CNBC

...

TipRanks 3d

Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from...

TipRanks 3d

Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from...

Analyst ratings

61%

of 31 ratings

Buy

35.5%

Hold

61.3%

Sell

3.2%

More BMY News

TipRanks 3d

Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider from Goldman Sachs maintained a Hold...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.